# Marketwise, Inc.: financial statements, quarterly

MKTW · Nasdaq · CIK 1805651 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mktw.md) · [Financials](/companies/mktw/financials.md) · [Filings](/companies/mktw/filings.md) · [Insiders](/companies/mktw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mktw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [106](/filings/0001628280-24-046024.md) | [112 d](/filings/0001805651-26-000016.md) | [109](/filings/0001628280-25-023467.md) | [105](/filings/0001628280-25-038608.md) | [97.2](/filings/0001805651-25-000008.md) | [97.5 d](/filings/0001805651-26-000016.md) | [83.5](/filings/0001805651-26-000043.md) | [80.0](/filings/0001628280-26-053921.md) | [81.3](/filings/0001805651-25-000008.md) | [83.4 d](/filings/0001805651-26-000016.md) | [77.0](/filings/0001805651-26-000043.md) | [75.8](/filings/0001628280-26-053921.md) |
| Cost of revenue | $m | [13.8](/filings/0001628280-24-046024.md) | [13.1 d](/filings/0001805651-26-000016.md) | [13.4](/filings/0001628280-25-023467.md) | [13.4](/filings/0001628280-25-038608.md) | [12.9](/filings/0001805651-25-000008.md) | [11.0 d](/filings/0001805651-26-000016.md) | [11.9](/filings/0001805651-26-000043.md) | [11.0](/filings/0001628280-26-053921.md) | [10.6](/filings/0001805651-25-000008.md) | [10.9 d](/filings/0001805651-26-000016.md) | [11.1](/filings/0001805651-26-000043.md) | [11.1](/filings/0001628280-26-053921.md) |
| Research and development | $m | [2.1](/filings/0001628280-24-046024.md) | [2.1 d](/filings/0001805651-26-000016.md) | [2.1](/filings/0001628280-25-023467.md) | [2.2](/filings/0001628280-25-038608.md) | [2.6](/filings/0001805651-25-000008.md) | [3.0 d](/filings/0001805651-26-000016.md) | [2.3](/filings/0001805651-26-000043.md) | [2.1](/filings/0001628280-26-053921.md) | [2.1](/filings/0001805651-25-000008.md) | [2.2 d](/filings/0001805651-26-000016.md) | [2.3](/filings/0001805651-26-000043.md) | [2.7](/filings/0001628280-26-053921.md) |
| Operating income | $m | [11.0](/filings/0001628280-24-046024.md) | [1.2 d](/filings/0001805651-26-000016.md) | [21.6](/filings/0001628280-25-023467.md) | [21.3](/filings/0001628280-25-038608.md) | [21.9](/filings/0001805651-25-000008.md) | [24.2 d](/filings/0001805651-26-000016.md) | [16.8](/filings/0001805651-26-000043.md) | [14.8](/filings/0001628280-26-053921.md) | [17.8](/filings/0001805651-25-000008.md) | [13.2 d](/filings/0001805651-26-000016.md) | [(1.1)](/filings/0001805651-26-000043.md) | [(4.3)](/filings/0001628280-26-053921.md) |
| Income tax | $m | [0.7](/filings/0001628280-24-046024.md) | [(0.2) d](/filings/0001805651-26-000016.md) | [0.7](/filings/0001628280-25-023467.md) | [0.8](/filings/0001628280-25-038608.md) | [1.0](/filings/0001805651-25-000008.md) | [0.8 d](/filings/0001805651-26-000016.md) | [1.0](/filings/0001805651-26-000043.md) | [0.6](/filings/0001628280-26-053921.md) | [1.1](/filings/0001805651-25-000008.md) | [(0.2) d](/filings/0001805651-26-000016.md) | [0.1](/filings/0001805651-26-000043.md) | [(0.2)](/filings/0001628280-26-053921.md) |
| Net income | $m | [0.1](/filings/0001628280-24-046024.md) | [0.1 d](/filings/0001805651-26-000016.md) | [1.7](/filings/0001628280-25-023467.md) | [1.5](/filings/0001628280-25-038608.md) | [1.7](/filings/0001805651-25-000008.md) | [2.1 d](/filings/0001805651-26-000016.md) | [0.9](/filings/0001805651-26-000043.md) | [1.3](/filings/0001628280-26-053921.md) | [1.5](/filings/0001805651-25-000008.md) | [1.9 d](/filings/0001805651-26-000016.md) | [(0.6)](/filings/0001805651-26-000043.md) | [(0.6)](/filings/0001628280-26-053921.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001628280-24-046024.md) | not reported | [0.85](/filings/0001628280-25-023467.md) | [0.80](/filings/0001628280-25-038608.md) | [0.87](/filings/0001805651-25-000008.md) | not reported | [0.41](/filings/0001805651-26-000043.md) | [0.53](/filings/0001628280-26-053921.md) | [0.58](/filings/0001805651-25-000008.md) | not reported | [(0.23)](/filings/0001805651-26-000043.md) | [(0.24)](/filings/0001628280-26-053921.md) |
| Basic EPS | $ per share | [0.00](/filings/0001628280-24-046024.md) | not reported | [0.90](/filings/0001628280-25-023467.md) | [0.81](/filings/0001628280-25-038608.md) | [0.88](/filings/0001805651-25-000008.md) | not reported | [0.43](/filings/0001805651-26-000043.md) | [0.55](/filings/0001628280-26-053921.md) | [0.60](/filings/0001805651-25-000008.md) | not reported | [(0.23)](/filings/0001805651-26-000043.md) | [(0.24)](/filings/0001628280-26-053921.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [194](/filings/0001628280-23-038021.md) | [155](/filings/0001805651-26-000016.md) | [131](/filings/0001628280-25-023467.md) | [109](/filings/0001628280-25-038608.md) | [94.1](/filings/0001805651-25-000008.md) | [97.9](/filings/0001805651-26-000016.md) | [79.2](/filings/0001805651-26-000043.md) | [69.1](/filings/0001628280-25-038608.md) | [50.5](/filings/0001805651-25-000008.md) | [70.1](/filings/0001628280-26-053921.md) | [52.7](/filings/0001805651-26-000043.md) | [32.9](/filings/0001628280-26-053921.md) |
| Current assets | $m | [313](/filings/0001628280-23-038021.md) | [268](/filings/0001628280-25-010781.md) | [233](/filings/0001628280-24-023639.md) | [198](/filings/0001628280-24-037041.md) | [172](/filings/0001628280-24-046024.md) | [169](/filings/0001805651-26-000016.md) | [153](/filings/0001628280-25-023467.md) | [130](/filings/0001628280-25-038608.md) | [117](/filings/0001805651-25-000008.md) | [132](/filings/0001628280-26-053921.md) | [112](/filings/0001805651-26-000043.md) | [87.2](/filings/0001628280-26-053921.md) |
| Total assets | $m | [452](/filings/0001628280-23-038021.md) | [397](/filings/0001628280-25-010781.md) | [359](/filings/0001628280-24-023639.md) | [315](/filings/0001628280-24-037041.md) | [278](/filings/0001628280-24-046024.md) | [260](/filings/0001805651-26-000016.md) | [240](/filings/0001628280-25-023467.md) | [212](/filings/0001628280-25-038608.md) | [202](/filings/0001805651-25-000008.md) | [218](/filings/0001628280-26-053921.md) | [202](/filings/0001805651-26-000043.md) | [186](/filings/0001628280-26-053921.md) |
| Current liabilities | $m | [362](/filings/0001628280-23-038021.md) | [374](/filings/0001628280-25-010781.md) | [334](/filings/0001628280-24-023639.md) | [313](/filings/0001628280-24-037041.md) | [284](/filings/0001628280-24-046024.md) | [260](/filings/0001805651-26-000016.md) | [248](/filings/0001628280-25-023467.md) | [240](/filings/0001628280-25-038608.md) | [229](/filings/0001805651-25-000008.md) | [234](/filings/0001628280-26-053921.md) | [229](/filings/0001805651-26-000043.md) | [248](/filings/0001628280-26-053921.md) |
| Total liabilities | $m | [699](/filings/0001628280-23-038021.md) | [685](/filings/0001628280-25-010781.md) | [629](/filings/0001628280-24-023639.md) | [579](/filings/0001628280-24-037041.md) | [525](/filings/0001628280-24-046024.md) | [477](/filings/0001805651-26-000016.md) | [457](/filings/0001628280-25-023467.md) | [439](/filings/0001628280-25-038608.md) | [428](/filings/0001805651-25-000008.md) | [432](/filings/0001628280-26-053921.md) | [429](/filings/0001805651-26-000043.md) | [453](/filings/0001628280-26-053921.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001628280-24-023639.md) | [0.7](/filings/0001628280-24-023639.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(13.3)](/filings/0001628280-23-038021.md) | [(11.1)](/filings/0001628280-25-010781.md) | [(9.4)](/filings/0001628280-24-023639.md) | [(23.7)](/filings/0001628280-24-037041.md) | [(19.5)](/filings/0001628280-24-046024.md) | [(12.5)](/filings/0001805651-26-000016.md) | [(15.8)](/filings/0001628280-25-023467.md) | [(15.8)](/filings/0001628280-25-038608.md) | [(14.5)](/filings/0001805651-25-000008.md) | [(11.7)](/filings/0001628280-26-053921.md) | [(12.2)](/filings/0001805651-26-000043.md) | [(33.5)](/filings/0001628280-26-053921.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [12.1 d](/filings/0001628280-24-046024.md) | [17.5 d](/filings/0001805651-26-000016.md) | [(18.5)](/filings/0001628280-25-023467.md) | [(3.8) d](/filings/0001628280-25-038608.md) | [(5.8) d](/filings/0001805651-25-000008.md) | [6.0 d](/filings/0001805651-26-000016.md) | [1.7](/filings/0001805651-26-000043.md) | [17.8 d](/filings/0001628280-26-053921.md) | [2.2 d](/filings/0001805651-25-000008.md) | [24.2 d](/filings/0001805651-26-000016.md) | [(2.1)](/filings/0001805651-26-000043.md) | [22.4 d](/filings/0001628280-26-053921.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-046024.md) | [0.0 d](/filings/0001805651-26-000016.md) | [0.0](/filings/0001628280-25-023467.md) | [0.0 d](/filings/0001628280-25-038608.md) | [0.0 d](/filings/0001805651-25-000008.md) | [0.1 d](/filings/0001805651-26-000016.md) | [0.0](/filings/0001805651-26-000043.md) | [0.1 d](/filings/0001628280-26-053921.md) | [0.0 d](/filings/0001805651-25-000008.md) | [0.2 d](/filings/0001805651-26-000016.md) | [0.5](/filings/0001805651-26-000043.md) | [0.2 d](/filings/0001628280-26-053921.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-046024.md) | [0.0 d](/filings/0001805651-26-000016.md) | not reported | not reported | [0.0 d](/filings/0001805651-25-000008.md) | [0.0 d](/filings/0001805651-26-000016.md) | [0.0](/filings/0001805651-26-000043.md) | [1.9](/filings/0001628280-25-038608.md) | [1.1](/filings/0001805651-25-000008.md) | [0.5 d](/filings/0001805651-26-000016.md) | [0.1](/filings/0001805651-26-000043.md) | [0.3 d](/filings/0001628280-26-053921.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.6](/filings/0001628280-23-038021.md) | [30.5](/filings/0001628280-24-023639.md) | [31.8](/filings/0001628280-24-037041.md) | [33.6](/filings/0001628280-24-046024.md) | [2.0](/filings/0001628280-25-023467.md) | [1.9](/filings/0001628280-25-038608.md) | [2.0](/filings/0001805651-25-000008.md) | [2.2](/filings/0001805651-26-000043.md) | [2.4](/filings/0001628280-26-053921.md) | [2.6](/filings/0001805651-25-000008.md) | [2.5](/filings/0001805651-26-000043.md) | [2.6](/filings/0001628280-26-053921.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.